Skip to main content
letter
. 2021 Mar 14;193(4):692–696. doi: 10.1111/bjh.17402

Fig 2.

Fig 2

Comparative analyses between the myeloproliferative neoplasm (MPN)‐positive group and the healthy control‐positive group (both groups include those with characteristic history or confirmed previous infection using polymerase chain reaction or antibody testing) and the negative group (not meeting any of these criteria) for CD4+ cell expression of tumour necrosis factor α (TNFα) and interleukin 2 (IL‐2) in response to the M and S proteins.